Systems Biology in Cancer Research and Drug DiscoveryAsfar S Azmi Springer Science & Business Media, 29.09.2012 - 423 Seiten Systems Biology in Cancer Research and Drug Discovery provides a unique collection of chapters, by world-class researchers, describing the use of integrated systems biology and network modeling in the cancer field where traditional tools have failed to deliver expected promise. This book touches four applications/aspects of systems biology (i) in understanding aberrant signaling in cancer (ii) in identifying biomarkers and prognostic markers especially focused on angiogenesis pathways (iii) in unwinding microRNAs complexity and (iv) in anticancer drug discovery and in clinical trial design. This book reviews the state-of-the-art knowledge and touches upon cutting edge newer and improved applications especially in the area of network modeling. It is aimed at an audience ranging from students, academics, basic researcher and clinicians in cancer research. This book is expected to benefit the field of translational cancer medicine by bridging the gap between basic researchers, computational biologists and clinicians who have one ultimate goal and that is to defeat cancer. |
Im Buch
Ergebnisse 1-5 von 82
... treated with low dose of chemical hepatocarcinogens and hormones. It is of utmost relevance that the same metabolic features have been found in preneoplastic lesions induced in rat livers by transduction of retroviral vectors containing ...
... treated conditions. NBE decreases as tumour cells become more rounded and lose their malignant characteristics, among which ... treatment induces a dramatic two-fold reduction, mirrored by parallel changes in nuclear and membrane shape ...
... treated cells, highlighted significant differences between the two groups on the first four PCs at each experimental time and on the PC5 at 48 and 96 h, thus showing that the treatment was the main driving force of between samples ...
... treated groups at 96 h is highlighted by the black line. Under treatment, breast cancer cells underwent a transition from a glycolytic towards an oxidative metabolic phenotype (modified from M. Bizzarri et al. (2010)) PC1 PC2 Factor ...
... treated groups seemed to occur between 48 and 72 h, while in the case of metabolic description, the two experimental groups diverged between 72 and 96 h. These preliminary data suggest that the structural reorganization fostered by EMF ...
Inhalt
Systems Approaches to Understand Cancer Progression | 165 |
Systems and Network Biology in Decoding miRNA Complexity | 246 |
Network Modeling in Cancer Drug Discovery and Clinical Trials | 307 |
Erratum | 418 |
Index | 419 |